Ceribell (CBLL) Q2 2026 earnings review
Core Growth Excels, But Credit Facility Raises Burn Rate Questions
Ceribell delivered another quarter of remarkably consistent top-line execution, growing revenue 33% YoY to $28.1M and expanding active accounts to 712. The most critical development is the formal CMS approval of the NTAP for delirium monitoring—a massive commercial de-risking event that unlocks a $1B market. However, operating expenses are running hot (+37% YoY), driven by the ongoing Natus patent litigation. While Adjusted EBITDA remained stable, GAAP net loss widened substantially. Management previously insisted they had sufficient cash to reach breakeven, but the sudden addition of a $60M credit facility suggests the cash burn is heavier than anticipated.
🐂 Bull Case
The CMS officially granted the New Technology Add-On Payment (NTAP) for delirium monitoring, effective Oct 1, 2026. This transitions a highly-touted clinical narrative into an immediately monetizable $1B TAM catalyst.
Total revenue grew 33% YoY, marking the company's continuous streak of sequential revenue growth. With 712 active accounts (up from 584 a year ago), the 'land and expand' strategy is working flawlessly.
🐻 Bear Case
The Natus patent lawsuit is severely impacting the bottom line. GAAP net loss widened to $19.3M (from $13.6M last year), entirely offsetting the impressive gross profit dollars generated by sales growth.
Management spent late 2025 and early 2026 assuring investors they would reach cash flow breakeven with cash on hand. The newly secured $60M credit facility contradicts this confidence and suggests heavier expected burn.
⚖️ Verdict: 🟢
Bullish. The widening GAAP losses are a near-term headache driven by litigation, but the underlying business fundamentals are stellar. Securing the NTAP for delirium is a fundamental game-changer that sets up massive leverage for 2027.
Key Themes
Delirium NTAP Catalyst Secured
The biggest fundamental news in the quarter was CMS formally granting the NTAP for Ceribell's delirium monitoring solution, taking effect October 1, 2026. Management has previously sized this as a $1 billion 'greenfield' opportunity, given 60-80% of ventilated ICU patients are affected and Ceribell holds the only FDA-cleared diagnostic. This regulatory win ensures hospitals are economically incentivized to adopt the technology, paving the way for a major revenue acceleration in late 2026 and 2027.
The Breakeven Narrative Contradiction
In multiple previous earnings calls (25Q3, 25Q4, 26Q1), management confidently reiterated their 'North Star' was achieving cash flow breakeven with cash on hand (which stood at $129.3M this quarter). However, securing a new $60M credit facility in August 2026 contradicts this narrative. Operating expenses jumped 37% YoY to $45.9M. While having a capital buffer is prudent, investors should monitor if the Natus litigation and commercial ramp are burning more cash than internally forecasted.
Litigation Costs Obscure Core Operating Leverage
The divergence between GAAP Net Loss (-$19.3M) and Adjusted EBITDA (-$9.8M) is stark. The core business is actually demonstrating Stable operating leverage—Adjusted EBITDA loss slightly improved YoY from -$10.0M despite massive revenue growth. The $9.5M delta is primarily driven by the Natus patent infringement suit (initiated July 2025) and stock-based compensation. Until the ITC litigation resolves, GAAP profitability will remain elusive.
Vietnam Supply Chain Shields Margins
Gross margins hit an astounding 92% in Q2, up from 88% a year ago. While part of this was a one-time benefit from IEEPA tariff refunds, the underlying margin profile is being successfully defended by the new manufacturing line in Vietnam. This strategic move effectively neutralizes the aggressive China tariff headwinds (which spiked to ~55%) that management warned about in late 2025.
Next-Generation Hardware Foundation Approved
Ceribell received multiple FDA 510(k) clearances for new recorder and headband designs, alongside clearances for Epileptiform Abnormality Detection and Artifact Reduction algorithms. This hardware refresh is crucial as the company transitions from a single-use seizure detector to a comprehensive 'vital sign' brain monitoring platform handling pediatrics, neonates, and delirium.
Other KPIs
Subscription revenue continues to scale predictably, up 30% YoY from $5.3M in 25Q2. This recurring revenue stream, driven by the Clarity software installed base, remains highly complementary to the $21.2M in hardware product revenue (+33% YoY).
Accelerating. The company ended the quarter with 712 active hospitals, up 32 net new accounts sequentially from 680 in Q1. This matches the record pace of 33 additions in Q1, proving that the newly expanded sales force (up to ~55 territories) is fully productive.
An exceptional print, up from 88% in the prior year and 87% in Q1. While investors should back out the one-time tariff refund to find the normalized rate, it clearly demonstrates that Ceribell commands immense pricing power and has successfully navigated supply chain cost pressures.
Guidance
Accelerating. Management raised the full-year guidance range from the prior $112M-$116M. The new midpoint ($115.5M) implies a robust 28% to 31% YoY growth rate over FY25. This reflects high confidence in the core business overcoming the typical Q2/Q3 seasonal ICU census slowdowns.
Key Questions
Normalized Gross Margin
Gross margin spiked to 92% due to one-time tariff refunds and Vietnam manufacturing benefits. Can you quantify the exact dollar impact of the tariff refund so we can understand the normalized, go-forward gross margin run rate?
Capital Strategy Shift
You previously expressed high confidence in reaching cash flow breakeven with the cash currently on your balance sheet. What changed internally that drove the decision to secure a new $60M credit facility?
Delirium NTAP Economics
With the CMS NTAP effective October 1, 2026, how will this influence your pricing strategy for the delirium module? Will you charge a separate subscription tier, or use it primarily to drive higher volume hardware utilization?
Litigation Timeline
Given the substantial drag of IP litigation costs on your operating expenses, what are the updated expectations for key milestone dates or potential resolutions in the Natus ITC and District Court cases?